Robert Hromas, MD, Dean, Joe R. and Teresa Lozano Long School of Medicine and Vice President for Medical Affairs, UT Health San Antonio

A year of transformative progress

May 13, 2023

UT Health San Antonio’s Joe R. and Teresa Lozano Long School of Medicine Dean Robert Hromas, MD, identifies four areas of focus of the Mays Cancer Center in its quest to end cancer for communities in South Texas and beyond.

Sandeep Burma, PhD, Professor of Neurosurgery and Biochemistry and Structural Biology; Mays Family Foundation Distinguished Chair in Oncology; Vice Chair for Research, Department of Neurosurgery

The biology of cancer

May 13, 2023

Mays Cancer Center researchers are making significant strides in understanding risk factors and conditions that cause cancers to develop and progress and assessing impacts on the health and recovery of patients with cancer.

Ratna Vadlamudi, PhD, Professor and Vice Chair for Research, Department of Obstetrics and Gynecology

Promising compound kills range of hard-to-treat cancers

May 13, 2023

Ratna Vadlamudi, PhD, a professor of obstetrics and gynecology at the Mays Cancer Center, is researching compounds that can target cancer cells to stop their growth.

Mosaic image of hands touching

New discoveries in pediatric cancer research

May 13, 2023

The findings from recent research studies in pediatric cancer offer hope for drug development.

Mosaic art

Disparities discussed at San Antonio Breast Cancer Symposium

May 13, 2023

Researchers from the Mays Cancer Center at UT Health San Antonio presented results of multiple lines of study during the San Antonio Breast Cancer Symposium, operated in conjunction with the American Association of Cancer Research.

Researcher in lab

How COVID-19 vaccines affect patients with cancer

May 13, 2023

Mays Cancer Center researchers are studying how the immune system responds to the novel coronavirus vaccine in patients with cancer, and why many Black patients with cancer experienced significantly worse outcomes after COVID-19 diagnosis than non-Hispanic white cancer patients.

Uncovering Repair Mechanisms to Fix DNA Double-Strand Breaks

July 21, 2021

Researchers at the Mays Cancer Center are studying the most toxic and carcinogenic kind of DNA damage — DNA double-stand break which can be caused by radiation used to kill cancer cells. Their findings can lead to new more effective treatments.

Groundbreaking Work on Connexins Leads to Potential Breast Cancer Drug

July 21, 2021

Jean Jiang, PhD, and her team of researchers are building on their innovative discoveries on connexin channels by developing custom antibodies to stimulate the opening of hemichannels in bone cells to protect skeletal tissue from the invasion of breast cancer cells.

Anti-Depressant Drug Offers Hope to Treat, Prevent Breast Cancer

July 21, 2021

A discovery in the research lab of Manjeet Rao, PhD, has led to a clinical trial — conducted by physician-scientist Virginia Kaklamani, MD, DSc — repurposing imipramine, a drug originally designed to treat depression, to determine if the drug not only treats but also prevents breast cancer.

Studying Cork Tree Extract and Exercise as Treatments for Prostate Cancer

July 21, 2021

Darpan Patel, PhD, and lead investigator A. Pratap Kumar, PhD, studied amurense, an extract from the bark of the Amur cork tree native to China, in mouse models to determine its potential as a therapeutic in treating prostate cancer. Research proved it is just as effective as exercise in preventing the progression.

2020 Discovery of the Year Awarded to Ricardo Aguiar, MD, PhD

July 20, 2021

The Mays Cancer Center presented the 2020 Discovery of the Year award to Ricardo Aguiar, MD, PhD, for his team’s breakthrough discovery in their basic biological research on diffuse large B-cell lymphoma (DLBCL). a common and often fatal hematological malignancy.

Researchers Battle Therapy-Resistant Cancer Cells by Identifying Aggressive Gene Enhancers

July 20, 2021

New research at the Mays Cancer Center has revealed one reason breast cancer tumor cells are so notoriously resistant to treatment. The finding has important implications in the prospect of developing first-in-class therapies that target the mechanisms in which DNA is ready by the cancer cell.